Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Intelligent Personalised Disease Monitoring Device: a-Doc

Projektbeschreibung

Mit simpler Speichelprobe die Aktivität von Autoimmunerkrankungen überwachen

Autoimmunkrankheiten wie Multiple Sklerose und rheumatoide Arthritis können schwerwiegend verlaufen und dabei starke Schmerzen und viel Leid verursachen. Zudem müssen die Betroffenen trotz stabiler Medikation mit unvorhersehbaren Schüben leben. Das EU-finanzierte Projekt a-Doc schlägt nun eine Methode der zu Hause erfolgenden schnellen und nichtinvasiven Messung der Krankheitsaktivität vor. Diese technologieintensive Innovation nutzt einen neuartigen Biomarkeralgorithmus auf der Grundlage des Gonadotropin-Releasing-Hormons aus, das ein gängiger Biomarker für verschiedene Autoimmunerkrankungen ist. Beruhend auf diesem Ansatz wird die a-Doc-Lösung anhand einer Speichelprobe die Krankheitsaktivität anzeigen und einen genauen Momentanwert liefern können.

Ziel

600m people globally suffer from autoimmune diseases such as rheumatoid arthritis (RA), psoriasis, and multiple sclerosis. The symptoms can be severe, causing intense pain and suffering for patients. The cost of RA alone for Europe is €45.3 billion p.a.

A growing need: Unlike diabetes patients for example who can measure their own blood sugar levels, there is currently no method to measure disease activity quickly and accurately for autoimmune patients, non-invasively at home. Furthermore, most autoimmune diseases have unpredictable flares in disease activity despite stable medication, and the causes of such flares differ between patients and are largely unidentifiable.

Our deep-tech innovation is an Artificial Intelligence approach to the Monitoring of Autoimmune Diseases at Home with a Novel Biomarker Algorithm: Through 15 years of research in this field, the founder of Kaass Discovery, Dr Anita Kaass, has shown a key biomarker, Gonadotropin releasing hormone (GnRH), is common to several autoimmune diseases. It has been scientifically shown that GnRH levels increase with increasing disease activity.

Kaass Discovery is developing a highly novel, deep tech solution to allow autoimmune disease patients to self-manage their conditions and minimize or even eliminate the symptoms of autoimmune diseases. The solution, which we call ‘a-Doc’, uses a saliva sample to indicate disease activity and provide an accurate, instantaneous value. In line with this need, it is also low cost, accurate and simple to use ensuring it is suitable for home use. The data collected from the device will be sent to the Kaass Discovery Cloud for improving the predictive analytical models, and giving an individualised meaningful result to the user on their mobile device

The aims of the Women TechEU programme align perfectly with the needs of Kaass Discovery. The business coaching support provided will ensure we are prepared and able to successfully commercialise this exciting technology.

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-CSA - HORIZON Coordination and Support Actions

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-EIE-2021-SCALEUP-01

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

KAASS DISCOVERY AS
Netto-EU-Beitrag
€ 75 000,00
Adresse
SKRAPEKLEWEGEN 4
3937 Porsgrunn
Norwegen
KMU
Ja
Region
Norge Agder og Sør-Østlandet Vestfold og Telemark
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
Keine Daten